非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2023.02.012

摘要/Abstract

摘要： 目的探讨非酒精性脂肪肝病(NAFLD)患者血清miR-183-5p和miR-96-5p水平变化及其临床意义。方法 2019年11月～2022年1月我院诊治的NAFLD患者62例和同期性别和年龄相匹配且无过量饮酒史的健康体检者80例,采用实时荧光定量RT-PCR法检测血清miR-183-5p和miR-96-5p水平,应用多因素Logistic回归分析NAFLD发生的危险因素,应用受试者工作特征曲线(ROC)下面积(AUC)评估指标诊断严重脂肪性肝病的效能。结果 NAFLD患者BMI、胰岛素抵抗指数(HOMA-IR)、空腹血糖(FPG)和血脂水平显著高于健康人(P＜0.05),血清miR-183-5p和miR-96-5p水平分别为(0.8±0.2)和(1.2±0.3),显著低于健康人【分别为(1.4±0.4)和(2.3±0.6),P＜0.05】; 17例重度NAFLD患者血清miR-183-5p和miR-96-5p水平分别为(0.4±0.1)和(0.8±0.2),显著低于21例中度患者【分别为(0.8±0.2)和(1.2±0.3),P＜0.05】或24例轻度患者【分别为(1.1±0.3)和(1.5±0.4),P＜0.05】;经Logistic回归分析结果显示,BMI、HOMA-IR、FPG、甘油三酯、低密度脂蛋白胆固醇以及血清miR-183-5p和miR-96-5p低水平是NAFLD发生的独立危险因素(P＜0.05);应用血清miR-183-5p和miR-96-5p联合检测评估重度NAFLD发生的AUC为0.821,显著高于两项指标单独评估的0.713或0.718(P＜0.05),其准确度、灵敏度和特异度分别达到77.4%、76.5%和77.8%。结论 NAFLD患者血清miR-183-5p和miR-96-5p呈低水平,其水平越低,可能预示着肝内脂肪变程度越重,即它们的血清水平可在一定程度上反映疾病的严重程度,可作为诊断和评估病情的分子标志物,值得进一步研究。

关键词: 非酒精性脂肪性肝病, 微小RNA-183-5p, MiR-96-5p, 诊断

Abstract: Objective The aim of this study was to explore the implications of microRNA(miR)-183-5p and miR-96-5p level changes in patients with nonalcoholic fatty liver diseases (NAFLD). Methods 62 patients with NAFLD and 80 healthy individuals with matched gender and age and without history of excessive drinking were enrolled in our hospital between November 2019 and January 2022. Serum miR-183-5p and miR-96-5p levels were detected by real-time fluorescent quantitative RT-PCR, and the factors impacting the occurrence of severe NAFLD was analyzed by multivariate Logistic regression analysis. The diagnostic performance of miR-183-5p and miR-96-5p in predicting the severity of NAFLD was evaluated by the area under the receiver operating characteristic curves(AUC). Results The body mass index, HOMA-IR, fasting plasma glucose and blood fat levels in patients with NAFLD were significantly higher than in healthy persons (P＜0.05), while serum miR-183-5p and miR-96-5p levels were (0.8±0.2) and (1.2±0.3), much lower than [(1.4±0.4) and (2.3±0.6), respectively, P＜0.05] in healthy control; serum miR-183-5p and miR-96-5p levels in 17 patients with severe NAFLD were (0.4±0.1) and (0.8±0.2), significantly lower than [(0.8±0.2) and (1.2±0.3), respectively, P＜0.05] in 21 patients with moderate NAFLD or [(1.1±0.3) and (1.5±0.4), respectively, P＜0.05] in 24 patients with mild NAFLD; the multivariate Logistic regression analysis revealed that the BMI, HOMA-IR, FPG, triglyceride and low-density lipoprotein cholesterol as well as serum miR-183-5p and miR-96-5p levels were the independent risk factors for the existence of severe NAFLD(P＜0.05); the AUC was 0.821, with the accuracy, sensitivity and specificity of 77.4%, 76.5% and 77.8% when the combination of serum miR-183-5p and miR-96-5p levels was applied to predict the severe NAFLD, much superior to anyone of the two parameters alone (with the AUC of 0.713 or 0.718, respectively, P＜0.05). Conclusion Serum miR-183-5p and miR-96-5p levels are down-regulated in patients with NAFLD, and the lowest the serum levels of them, the more severe of the NAFLD, which hints the more severe intrahepatic steatosis, and warrants further clinical investigation.

Key words: Nonalcoholic fatty liver diseases, MicroRNA-183-5p, MiR-96-5p, Diagnosis

刘岗, 张浩, 胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 197-201.

Liu Gang, Zhang Hao, Hu Jun. Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(2): 197-201.

参考文献

[1] Troelstra MA, Witjes JJ, Dijk AM, et al. Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: The Amsterdam NAFLD-NASH cohort. J Magn Reson Imaging, 2021, 54(6): 1937-1949.
[2] Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med, 2020, 17(4): e1003100.
[3] Ma Z, Xu C, Kang X, et al. Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. J Transl Med, 2020, 18(1): 133.
[4] Miele L, Alberelli MA, Martini M, et al. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Transl Res, 2021, 23(1): 24-38.
[5] Zhu F, Li X. Fructose intake is not associated to the risk of hepatic fibrosis in patients withnon-alcoholic fatty liver disease (NAFLD). Clin Nutr, 2021, 40(6): 3827.
[6] Amerikanou C, Papada E, Gioxari A, et al. Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action. Pharmacol Res, 2021, 17(1): 105753.
[7] 中国肝病学会脂肪肝与酒精性肝病研究组. 非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志, 2006, 14(3): 161-163.
[8] Li Y, Xu J, Lu Y, et al. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metab, 2021, 33(10): 2004-2020.
[9] Ajaz S, McPhail MJ, Gnudi L, et al. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion, 2021, 57(5): 119-130.
[10] 黄蝶, 田昊宇, 李异玲. 非酒精性脂肪性肝病血清标志物研究进展. 实用肝脏病杂志, 2022, 25(2): 297-300.
[11] Anderson O, Guttilla Reed IK. Regulation of cell growth and migration by miR-96 and miR-183 in a breast cancer model of epithelial-mesenchymal transition. PLoS One, 2020, 5(5): e0233187.
[12] Chava S, Reynolds CP, Pathania AS, et al. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol, 2020, 14(1): 180-196.
[13] Zhou X, Yuan Y, Teng F, et al. Obesity-induced upregulation of microRNA-183-5p promotes hepatic triglyceride accumulation by targeting the B-cell translocation gene 1. Life Sci, 2021, 26(8): 119011.
[14] Yan S, Wang H, Chen X, et al. MiR-182-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-C. Cancer Lett, 2020, 488(28): 18-26.
[15] Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem, 2021, 281(30): 21183-21197.
[16] Chandel R, Saxena R, Das A, et al. Association of rno-miR-183-96-182 cluster with diethyinitrosamine induced liver fibrosis in Wistar rats. J Cell Biochem, 2018, 119(5): 4072-4084.
[17] Wang H, Ma Z, Liu X, et al. MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN. Biomed Pharmacother, 2019, 111(5): 1103-1111.
[18] Chen D, Xu L, Wu J, et al. Downregulating miR-96-5p promotes proliferation, migration, and invasion, and inhibits apoptosis in human trophoblast cells via targeting DDAH1. Reprod Biol, 2021, 21(1): 100474.
[19] Derany MO, AbdelHamid SG. Upregulation of miR-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: Emphasis on caspase-2 signaling inhibition. Biochem Pharmacol, 2021, 190(8): 114624.
[20] Dong XZ, Song Y, Lu YP, et al. Sanguinarine inhibits the proliferation of BGC-823 gastric cancer cells via regulating miR-96-5p/miR-29c-3p and the MAPK/JNK signaling pathway. J Nat Med, 2019, 73(4): 777-788.
[21] Fisher L. Retraction: MiR-182-5p and miR-96-5p increased hepatocellular carcinoma cell mobility, proliferation and cisplatin resistance partially by targeting RND3. RSC Adv, 2021, 11(7): 4166.

非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*

Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	白婷婷, 刘钰懿, 陈东风. 肝脏血管性疾病诊断与鉴别诊断[J]. 实用肝脏病杂志, 2023, 26(2): 153-155.
[2]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[3]	范明芳, 田瑛, 周倩, 接贵涛, 刘淑芳. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 185-188.
[4]	郝蕾, 高卫东, 胡娟娟, 张琳, 邢亚恒. 非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 189-192.
[5]	方颖, 金家东, 汪芾, 周达. 新冠疫情期间情绪对非酒精性脂肪性肝病患者血生化指标的影响^*[J]. 实用肝脏病杂志, 2023, 26(2): 193-196.
[6]	李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.
[7]	舒开凤, 糜春, 刘微微, 尹修文. 高频超声联合彩色多普勒超声诊断胆囊息肉样病变价值分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 286-289.
[8]	黄淡霞, 招志辉, 萧月兴, 何艳青. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
[9]	陈凤莲, 朱青蓝, 朱伶俐, 陈国飞. 非酒精性脂肪性肝病患者外周血恒定自然杀伤T细胞和CD4⁺/CD8⁺T细胞活化差异研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 31-34.
[10]	徐伟强, 刘淑萍, 李潇萌. 体检人群非酒精性脂肪性肝病检出率及其危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 35-38.
[11]	刘南南, 李卫, 赵守松. 简化版动物命名试验对肝硬化并发轻微性肝性脑病的诊断价值及相关因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 83-86.
[12]	江慧珍, 陈俊, 陈春美, 闫海金. 动态增强磁共振定量参数诊断肝脏占位性病变良恶性效能分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 100-103.
[13]	陈怡, 朱友, 周希乔. 甲状腺激素与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 145-148.
[14]	韩芳, 李佳峥, 南月敏. 肝硬化并发急性肾损伤诊治进展[J]. 实用肝脏病杂志, 2022, 25(6): 768-771.
[15]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.